(RTTNews) – The European Commission announced Friday that it signed an agreement with Sanofi and GlaxoSmithKline to protect up to three hundred million doses of their possible COVID-19 vaccine.
The committee said the agreement marks the time of the vaccine safety agreement, following an agreement already signed with AstraZeneca. Last month, the European Commission reached an agreement with AstraZeneca to deliver up to 400 million doses of its AZD1222 COVID-19 vaccine.
The commission also said it proceeded to discuss similar agreements with other vaccine brands: Johnson
Sanofi said the agreement would allow the acquisition of a COVID-19 vaccine for all EU member states, which can administer doses reserved for low- and middle-income countries.
The candidate vaccine is based on the generation of recombinant protein used through Sanofi to produce a flu vaccine and the generation of adjuvants established by GSK.
Sanofi and GlaxoSmithKline began a Phase 1/2 test of vaccine progression in September, followed by a Phase 3 test through the end of 2020 if approved, companies aim to make the vaccine available until 2021.
Sanofi and GlaxoSmithKline, who have also signed supply agreements in the United States and the United Kingdom, said they were stepping up antigen and adjuvant manufacturing with the goal of generating up to one billion doses consistent with the year in general to meet a pushing for the global call for vaccines.